122 results on '"Lohaus F"'
Search Results
2. Stereotactic radiosurgery and radiotherapy for resected brain metastases: current pattern of care in the Radiosurgery and Stereotactic Radiotherapy Working Group of the German Association for Radiation Oncology (DEGRO)
3. Correction to: Stereotactic radiosurgery and radiotherapy for resected brain metastases: current pattern of care in the Radiosurgery and Stereotactic Radiotherapy Working Group of the German Association for Radiation Oncology (DEGRO)
4. Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy
5. Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease
6. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases
7. Interobserver variability in target volume delineation of hepatocellular carcinoma: An analysis of the working group “Stereotactic Radiotherapy” of the German Society for Radiation Oncology (DEGRO)
8. PD-0064 Metastases-directed SRT combined with systemic therapy: 2y results of the TOaSTT real-world database
9. PO-1094 Use of an individual abdominal corset in patients with upper-GI tumors treated with proton therapy
10. PO-0915 Integral multi-scenario robustness evaluation of anatomical robust optimization in head and neck
11. OC-0496 Deep-learning based estimation of locoregional control for patients with locally advanced HNSCC
12. OC-0390 TCGA molecular subclassification is prognostic for LRC of HNSCC after postoperative RCTx
13. OC-0275 Safety and efficacy of concurrent SRT and targeted- or immunotherapy for melanoma brain metastases
14. OC-0166 Cumulative metastases volume, not number of brain metastases predicts survival in melanoma patients
15. OC-0059 Stereotactic radiotherapy for oligoprogressive NSCLC: clinical scenarios affecting survival
16. OC-0517: Robust optimization is not sufficient to account for anatomical changes in head and neck IMPT
17. OC-0508: Identification of tumour sub-volumes for improved radiomic risk modelling in locally advanced HNSCC
18. OC-0324: Immune contexture in SCCHN and outcome after chemoradiotherapy in an uni- and multicentric cohort
19. OC-0276: Combining different genomic signatures to improve the prognostic power for LRC after PORT-C in HNSCC
20. PV-0044: Repeat sbrt for pulmonary oligo-metastases
21. PV-0043: Histology as predictor for outcome following SBRT in NSCLC patients with lung oligo-metastases
22. EP-1253: Interobserver variability in the target delineation of hepatocellular carcinoma
23. PO-0616: HPV, CSC marker expression and tumor hypoxia as prognosticators for LRC in patients with HNSCC
24. PO-0619: Comparison of a nanoString and RNA microarray gene signature predicting LRC after PORT-C in HNSCC
25. Interobservervariabilität bei der Zielvolumendefinition für hepatozelluläre Karzinome : Eine Analyse der Arbeitsgruppe „Stereotaktische Radiotherapie“ der Deutschen Gesellschaft für Radioonkologie (DEGRO).
26. SBRT for Lung Metastases: A Pooled Analysis of 651 Patients and 868 Lesions of the German Working Group Stereotactic Radiotherapy
27. SP-0142: Radiation therapy for castrate resistant oligometastatic patients.
28. OC-0451: Tumour volume, hypoxia and cancer stem cells as prognosticators for LRC after primary RCT in HNSCC.
29. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
30. PO-1304 Impact of blood parameters and normal tissue dose on overall survival in esophageal cancer patients.
31. OC-0256 Biomarker development from joint analyses of HNSCC xenografts and patients treated by PORT-C.
32. MO-0139 PORT-C improves LRC in a subset of patients with intermediate-risk HNSCC: A matched pair analysis.
33. OC-0582: Gene signatures predict loco-regional control after postoperative radiochemotherapy in HNSCC.
34. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.
35. PO-1332 OLI-P trial: pattern of progression after radiotherapy in PSMA-PET positive METs of prostate cancer.
36. PO-1540: Radiomic models for validation in patients with locally advanced HNSCC treated with primary RTCx.
37. OC-0570: Validating gene signatures in locally advanced HNSCC patients treated by PORT-C and in xenografts.
38. OC-0453: Efficacy and safety of stereotactic radiotherapy combined with TKIs for metastatic lesions.
39. 173P Stereotactic radiotherapy concurrent to immune or targeted therapy for oligometastatic NSCLC: Clinical scenarios affecting survival.
40. The value of subcutaneous xenografts for individualised radiotherapy in HNSCC: Robust gene signature correlates with radiotherapy outcome in patients and xenografts.
41. Multitask Learning with Convolutional Neural Networks and Vision Transformers Can Improve Outcome Prediction for Head and Neck Cancer Patients.
42. DNA-Methylome-Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy.
43. Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy.
44. Reduction of intrafraction pancreas motion using an abdominal corset compatible with proton therapy and MRI.
45. Integrated radiogenomics analyses allow for subtype classification and improved outcome prognosis of patients with locally advanced HNSCC.
46. Impact of Blood Parameters and Normal Tissue Dose on Treatment Outcome in Esophageal Cancer Patients Undergoing Neoadjuvant Radiochemotherapy.
47. A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT.
48. Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy.
49. Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P).
50. Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - Hypothesis generation on a multicentre cohort of the DKTK-ROG.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.